Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paltusotine (Primary) ; Paltusotine (Primary) ; Midazolam
  • Indications Acromegaly
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Crinetics Pharmaceuticals

    • Most Recent Events

    • 04 Sep 2020 According to a Crinetics Pharmaceuticals media release, data from this trial will be presented in a late-breaking session at the virtual European Congress of Endocrinology (eECE) 2020.
    • 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
    • 14 Mar 2019 According to a Crinetics Pharmaceuticals media release, final results from this trial will be presented at the upcoming ENDO 2019, the Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top